Astellas Deal History & Licensing Activity
Astellas is a large pharma headquartered in Japan. Over the past three years, Astellas has been involved in 24 licensing and acquisition transactions, with a primary focus on Bispecific Antibodies (11 deals). The company currently has 50 active clinical trials, primarily in Solid Tumors.
Deals (12mo)
4
Active Trials
50
Top Modality
Bispecific Antibodies
Focus Area
Solid Tumors
Astellas Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Astellas in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| muscle disorder capsid | Dyno | Gene Therapy | Unknown | license | Apr 2026 |
| muscle disorder capsid | Dyno Therapeutics | Gene Therapy | Unknown | license | Apr 2026 |
| Undisclosed | Astellas Pharma | Bispecific Antibodies | Preclinical | collaboration | Mar 2026 |
Astellas Pipeline Focus
Therapeutic areas and modalities where Astellas is most active based on deal history and clinical trial data.
Therapeutic Areas
Astellas Strategic Signals
Key indicators of Astellas's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
Astellas Clinical Pipeline
Astellas has 50 active clinical trials across 6 development phases.
2
Phase 4
7
Unknown
1
Not Applicable
22
Phase 1
11
Phase 2
7
Phase 3
See How Your Asset Matches Astellas's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Solid Tumors assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Women's Health Deal Benchmarks
Market sizing, deal terms, and competitive landscape for women's health
Bispecific Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for bispecific antibodies deals
ADC Benchmarks
Upfront, milestone, and royalty benchmarks for adc deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
About Astellas Licensing & Deal Activity
Astellas is a large pharma company based in Japan that has been actively engaged in licensing transactions across the biopharma landscape. With 24 deals over the past three years, Astellas ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Astellas include Solid Tumors (25 deals and trials), Oncology (17 deals and trials), Women's Health (6 deals and trials), and Hematological Malignancies (5 deals and trials). In terms of modality, Astellas has shown particular interest in bispecific antibodies, adc, gene therapy.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Astellas and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Astellas's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.